New York, NY - (NewMediaWire) - March 8, 2019 - Byzen Digital Inc. (OTC PINK: BYZN), a technology mergers and acquisitions company, today appointed Anthony Rose as Head one of new UK division, Startup Outreach.A LinkedIn influencer, business development professional and author based in Manchester, UK, Anthony is well connected to business and start-up communities in London, as well as the wider UK.This appointment marks a significant milestone in establishing Byzen Digital’s Startup Outreach program, which is set to be a source of potential mergers and acquisitions targets to the Company.Commenting on the appointment, Byzen Digital COO, Tom Beckett, said, “We are immensely pleased to welcome Anthony to the Byzen Digital team. We have worked closely with Anthony over the past year to strengthen the Company’s ties to the UK’s vibrant startup community and his input has been invaluable in establishing Byzen Digital’s foothold in the space. We look forward to working with Anthony to build and strengthen that success, and to developing a nationally recognised startup brand. By identifying and nurturing high-growth opportunities, our outreach division plays a central role in Byzen Digital’s strategy as the company secures its position in the tech M&A space.”Anthony Rose added, “Start-up activity in the UK is at record levels and there is no better time to be involved. With so much bright talent working on innovative tech to solve tough commercial and social challenges, the UK’s startup communities are a rich source of innovation. I’m incredibly excited to work with Byzen Digital at this pivotal moment in the company’s growth.” About Byzen Digital Inc.Byzen Digital is a high-growth organization focused on mergers and acquisitions in the tech space.Originally formed to service the growing blockchain sector, the company’s scope has quickly grown beyond its initial focus to incorporate start-ups and Small to Medium-sized Enterprises (SME) from the wider tech arena including cybersecurity, data storage, cloud-tech, analytics, software and digital applications. The Byzen Digital family provides vital strategic insight, global funding access and a robust corporate structure to support its incorporated ventures in positioning concepts for global success.Safe Harbor StatementThis press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to anticipated revenues, expenses, earnings, operating cash flows, the outlook for markets and the demand for products. Forward-looking statements are no guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statements. Such statements are based upon, among other things, assumptions made by, and information currently available to, management, including management's own knowledge and assessment of the Company's industry and competition. he company assumes no duty to update its forward-looking statements.Contacts: Chris Percy President Byzen Digital Inc. chris.p@byzendigital.com Investors: Stephanie Prince PCG Advisory 646-762-4518 sprince@pcgadvisory.com

The Company remains committed to closing the transaction in the near future MILTON, GA - (NewMediaWire) - March 8, 2019 - via NEWMEDIAWIRE -- Attis Industries Inc. (NASDAQ: ATIS) (the “Company” or “Attis”), a diversified innovation and technology holding company, today provided an update on the status of its previous announced purchase agreement with Sunoco LP to acquire and operate its corn ethanol plant and grain malting operation in Fulton, NY. While the acquisition has not been finalized, the transaction is still on track to close upon the satisfaction of customary closing conditions.As previously reported, the definitive asset purchase agreement calls for a total consideration for the divestiture of $20 million and includes a 10-year offtake agreement with Sunoco for the ethanol produced at the Fulton plant. Attis is expecting to finance the transaction with non-dilutive secured debt financing. The planned acquisition of Sunoco’s Fulton, NY ethanol plant is a key step in the Company’s long term vision of being a leader in the production of low carbon fuels and biobased products. Attis has plans for numerous improvements over the next 24 months to the Fulton plant with the goal of creating the industry’s premier renewable energy campus. “We remain confident the acquisition of the Fulton plant will be the first of many plants we acquire and/or build over the next 24-36 months,” said Jeffrey Cosman, CEO of Attis Industries Inc. “The Company is continuing to balance the close of the facility as quickly as possible around the end of the quarter with the expectation to secure a larger credit facility which will be used to quickly improve operations in Fulton, build and expand production fuels with our biodiesel and bio-refinery plant in Fulton, as well as begin building our first 3 independent bio-refineries in Georgia, South Carolina and Florida.” Attis Industries, Inc. Attis Industries Inc. (NASDAQ: ATIS) is a diversified innovation and technology holding company focused on developing and building businesses that play important roles in the new economy. We strive to encourage our employees to be entrepreneurs focused on innovation and technology. We will remain dynamic, persistent and motivated to our mission of winning. The growth of our company will rely on our integrity and our vision for the future. Today, each of Attis’ business sectors provide high growth opportunities that collectively account for more than a third of our nations GDP. For more information, visit: www.attisind.comForward-Looking StatementsAny statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “should,” “would” or similar words. You should consider these statements carefully because they discuss our plans, targets, strategies, prospects and expectations concerning our business, operating results, financial condition and other similar matters. These statements are subject to certain risks, uncertainties, and assumptions, including, but not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies; the ability of the Company to continue to meet the listing requirements of NASDAQ; the ability of the Company to execute on a business plan that permits the technologies and innovations businesses to provide sufficient growth, revenue, liquidity and cash flows for sustaining the Company’s ...

Sarasota FL - (NewMediaWire) - March 08, 2019 - First National Energy Corp (OTC: FNEC) is pleased to announce that its wind turbine technology has entered the commercialization stage and is now prepared for full scale deployment throughout North America.The wind turbine technology has 23 years of proven reliability and performance, hundreds of installations that continue to perform efficiently, and has received several industry recognition awards. Customer trials have been successfully completed since the technology was installed in North America in 2016.After more than 2 years of North American customer trials, the Company has received interest from a number of large organizations looking to adopt First National’s wind turbine technology. Discussions continue with the companies that participated in the trials regarding the integration of the technology into existing business models.Further, the company is in the process of solidifying a partnership with an experienced Management & Technical Engineering Services firm to manage and execute the overall deployment of the technology throughout North America. This partnership is expected to be secured and announced within the coming days. Ongoing additional updates from the Company are available by following First National Energy on Twitter @FNECorpVideos from FNEC can be viewed on FNEC’s YouTube channel: https://www.youtube.com/channel/UCQS0HDos9FDsBIG2vkU2YZAFor further information about First National Energy Corp, please visit: www.firstnationalenergy.comAbout First National Energy CorpFirst National Energy is dedicated to international research and evaluation of various wind turbine designs and technologies. The Company has since found and successfully acquired the perfect autonomous renewable energy solution for multiple critical and non-critical power applications. The technology has more than 23 years of proven reliability and performance, industry recognition awards, and hundreds of installations that continue to perform efficiently to date. After many years, this technology has evolved to become a completely fine tuned and state of the art solution chosen exclusively by military, national telecom corporations, large scale mining operations, municipalities to augment public utilities in remote areas and private users. To date, this technology has successfully produced in excess of 12,000 Megawatts of electrical power. The Company has also forged strategic and commercial relationships with large scale leading power generation contractors, engineering firms, producers, and industry experts in order to support future commercialization and of this technology suite which is now positioned for major deployment in USA, Canada, Europe and India.Safe Harbor StatementThis news release contains statements that involve expectations, plans or intentions (such as those relating to future business or financial results, new features or services, or management strategies) and other factors discussed from time to time in the Company's OTC Market or Securities and Exchange Commission filings. These statements are forward-looking and are subject to risks and uncertainties, so actual results may vary materially. You can identify these forward-looking statements by words such as "may," "should,", "will", "expect," "anticipate," "believe," "estimate," "confident," "intend," "plan" and other similar expressions. Our actual results, such as the Company's ability to finance, complete and consolidate acquisition of IP, assets and operating companies, could differ materially from those anticipated in these forward-looking statements as a result of certain factors not within the control of the company such as a result of various factors, including future economic, competitive, regulatory, and market conditions. The company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such ...

Pulsed Shortwave Neuromodulation Therapy (ActiPatch®) Study in Chronic Lower Back PainFrederick, MD - (NewMediaWire) - March 8, 2019 - BioElectronics Corporation (OTC PINK: BIEL) http://www.bielcorp.com is pleased to announce the commencement of a clinical study investigating the efficacy of ActiPatch in treating chronic lower back pain. The objectives of this additional back pain study are to support Mundipharma’s Australia and New Zealand sales and marketing, provide local economic data for product reimbursement, and to document ActiPatch’s effectiveness on central sensitization pain.Chronic low back pain is very challenging to treat given its association with “central sensitization”, as sufferers experience exaggerated pain perception [2] and are often resistant to standard treatments. Sree Koneru, Ph.D., VP of Product Development at BioElectronics, said, “There is already real-world and clinical evidence that ActiPatch is effective in reducing back pain [3]. More than 30 million Americans are affected by chronic low back pain, collectively spending more than $90 billion annually in treatment costs [1]”.The study will involve 142 subjects who have been suffering with low back pain for more than 3 months at the time of enrollment into the study, which is scheduled to take place over a 30-day period and involve two visits. During the first visit, baseline data about the subject, including pain intensity, functionality and sleep quality will be collected. They will then receive, randomly, either an active or sham ActiPatch device along with instructions on how to use it for the next 30-days. During the final follow up visit, additional data will be collected to evaluate improvements in pain and other outcome measures. Full details about the study can be found at the NIH’s clinical trials listing page (https://clinicaltrials.gov/ct2/show/NCT03828864), as well as the Australian New Zealand Clinical Trials Registry (https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12619000136101)The study is being conducted by the Pain Management Center of the prestigious Royal Prince Alfred Hospital in Sydney, Australia. The principal investigator (PI) leading the study is Graeme Campbell, a physiotherapist, supported by his team of physicians and clinical researchers.Dr. Sree Koneru, Ph.D. is presenting at the Australian Pharmacy Professional Conference RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy. For more information, please visit www.bielcorp.com.Contact: Paul Knopick pknopick@eandecommunications.com 940.262.3584

Houston, TX - (NewMediaWire) - March 08, 2019 - D3esports, a division of StemGen, Inc. (OTC: SGNI), has launched its first Virtual to Real Motorsports Experience Center with the Visit Houston Marketplace in Houston, Texas. The custom-built SIMxlr8 game pod is a state-of-the-art three-screen simulator, complete with interactive steering wheel and pedals, as well as a real racing seat. It offers the user the opportunity to feel the rush of high-speed racing both in the virtual realm and on the race track. The D3esports experience on the VisitHouston.com website marketplace is currently in the Top 5 marketplace destination for visitors, rated higher than the NASA Space Center Experience. The D3esports Virtual to Real Racing Experience offers 45 minutes of virtual laps on a state-of-the-art simulator, followed by 15 minutes of real laps on the track in a professional race car. The location is at the MSR Houston circuit in the southern suburbs of Houston and offered to anyone 15 years or older for a fee of $575 USD. (See https://experience.visithouston.com/checkout/3/visit-houston/8/houston-marketplace/product/14908/virtual-to-real-racing-experience) The SIMxlr8 game pod is evolutionary, patent-pending and fully upgradeable for a true driving experience and built by actual racers who know how to win on the track and online. After the Virtual to Real experience there is an opportunity to rent and get behind the wheel of a prototype race car and learn about aerodynamic with more to come on this virtual to real education platform. “Our engineers and drivers believe we have the best simulator products on the market for personal, educational, and commercial use,” said Simon Dawson, CEO/President of StemGen and D3esports. “The launch of the VisitHouston.com Virtual to Real Motorsports Experience Center has been incredibly successful in a short amount of time. The SIMxlr8 products line has been used in successful commercial and hospitality applications. When you become a retail or distributor partner, you have an instant new profit center. We’re excited about the interest in these Experience Centers and have big plans to open many more in the coming months and have global plans with this program.” As D3esports grows the virtual to real gaming platform in the motorsports industry, additional D3esports Experience Centers are planned to be launched in the coming months, including internationally. For more information on either the Experience Center or purchase of the D3esports game pods, contact info@d3esports.com. D3esports was founded in May 2018 and launched in July 2018 at Dave and Buster’s Houston flagship location. Through their D3 division, the company has extensive experience in real motorsports for over 40 years.ABOUT STEMGEN, INC.StemGen, Inc. (https://stemgencorp.com/), a Delaware corporation based in Angleton, Texas, is a virtual to real gaming platform in the motorsports industry. NOTICE REGARDING FORWARD LOOKING STATEMENTSSafe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.CONTACT: Barbara J. Burns, BurnsGroup PR barbara@burnsgrouppr.com or +1 770-329-7134

Industry Veteran John P. Sentman to Lead Strategic Sales and PartneringMIRAMAR, FL - (NewMediaWire) - March 08, 2019 - Olaregen Therapeutix, a subsidiary of Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is proud to announce the appointment of John P. Sentman as Vice President of Business Strategy. In his position, Mr. Sentman will lead and coordinate the activities and operations of the business strategy department responsible for executing all aspects of the organization’s overall business strategy, sales and market planning, and financial forecasts.Mr. Sentman has over 30 years of experience in commercial, marketing, and strategic planning roles within the medical device industry, primarily in the wound care field. He joins Olaregen from Integra Life Sciences where he was Senior Director of Global Marketing for Regenerative Technologies, overseeing brand marketing of the company’s soft tissue repair portfolio. Prior to Integra, Mr. Sentman held various sales, management, and marketing roles, both domestically and internationally over a 20-year career with ConvaTec, a leading manufacturer of wound care products. Mr. Sentman received his bachelor’s degree in finance from American University’s School of Business.“We are extremely pleased to have John leading business strategy, market development and the commercial launch of Excellagen,” said Anthony Dolisi, CEO of Olaregen and Chief Commercial Officer of Generex. “His extensive wound care experience and market knowledge will be instrumental to the company’s commercial success.”Mr. Sentman commented on his new position, “I welcome the opportunity to launch and build the Excellagen brand as the leading Cellular Tissue Product in treating hard-to-heal wounds, and I look forward to working closely with the Olaregen team.”About Generex Biotechnology Corp.Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products.Our newly formed, wholly-owned subsidiary, NuGenerex Distribution Solutions (NDS), integrates our MSO network with a pharmacy network, clinical diagnostic lab, durable medical equipment company (DME-IQ) and dedicated call center.About Olaregen TherapeuticsOlaregen Therapeutix, Inc. is a regenerative medicine company focused on the development, manufacturing and commercialization of products that fill unmet needs in the current wound care market. The company aims to provide advanced healing solutions that substantially improve medical outcomes while lowering the overall cost of care. Olaregen's first product introduction, Excellagen (flowable dermal matrix) is a topically applied product for dermal wounds and other indications. Excellagen is a FDA 510K cleared device for a broad array of dermal wounds, including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/ grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds, enabling Olaregen to market Excellagen in multiple vertical markets. Additionally, Excellagen can serve as an Enabling Delivery Platform for pluripotent stem cells, ...